Table 1.
Comparison between LI-RADS v2011 and v2014
| Category | LI-RADS v2011 | LI-RADS v2014 |
|---|---|---|
| LR treated | No LR-treated category | Any observation that has undergone locoregional treatment, regardless of the outcome |
| LR-1 and LR-2 | No difference between LI-RADS V2011 and LI-RADS v2014 | No difference between LI-RADS V2011 and LI-RADS v2014 |
| LR-3 Intermediate probability for HCC |
<20 mm arterial-phase iso- or hypoenhancing mass with ≤1 of the following: portal/delayed phase hypoenhancement, diameter increase by ≥10 mm in 1 year <20 mm arterial hyperenhancing mass with neither portal/delayed phase hypoenhancement nor ≥10 mm diameter increase within 1 year, or <20 mm arterial hyperenhancing nonmass-like and stable ≥20 mm iso- or hypoenhancing mass with neither portal/delayed phase hypoenhancement nor ≥10 mm diameter increase within 1 year, or ≥20 mm arterial hyperenhancing nonmass-like and stable |
<20 mm arterial-phase iso- or hypoenhancing with “washout” only or “capsule” only or threshold growth only or none ≥20 mm arterial-phase iso- or hypoenhancing without “washout,” “capsule,” or threshold growth <20 mm arterial-phase hyperenhancing without “washout,” “capsule,” or threshold growth |
| LR-4 | LR-4A | No A or B distinction |
| Probably HCC | <20 mm arterial iso- or hypoenhancing mass with both portal/delayed phase hypoenhancement and ≥10 mm diameter increase within 1 year <20 mm arterial-phase hyperenhancing mass with either portal/delayed phase hypoenhancement or ≥10 mm diameter increase within 1 year, but not both LR-4B ≥20 mm arterial-phase iso- or hypoenhancing mass with portal/delayed phase hypoenhancement or ≥10 mm diameter increase within 1 year or both ≥20 mm arterial-phase hyperenhancing mass with neither portal/delayed phase hypoenhancement nor ≥10 mm diameter increase within 1 year |
<20 mm arterial-phase iso- or hypoenhancing with ≥2 of the following: “washout,” “capsule,” or threshold growth <10 mm arterial-phase hyperenhancing with ≥1 of the following: “washout,” “capsule,” or threshold growth 10–19 mm arterial-phase hyperenhancing with “washout” only or “capsule” only or threshold growth only ≥20 mm arterial-phase iso- or hypoenhancing with ≥1 of the following: “washout,” “capsule,” or threshold growth ≥20 mm arterial hyperenhancing mass without “washout”, “capsule”, or threshold growth |
| LR-5 | LR-5A | No A or B distinction |
| Definitely HCC | ≥10 and <20 mm arterial hyperenhancing mass with both portal/delayed phase hypoenhancement and ≥ 10 mm diameter increase within 1 year LR-5B ≥20 mm arterial hyperenhancing mass with portal/delayed phase hypoenhancement or ≥10 mm diameter within 1 year or both |
10–19 mm arterial-phase hyperenhancing with ≥2 of the following: “washout,” “capsule,” or threshold growth ≥20 mm arterial hyperenhancing with ≥1 of: “washout,” “capsule,” or threshold growth |
| LR-5V | No LR-5V category | Mass with definite tumor in vein |
| LR-M | No LR-M category | Features suggestive of non-HCC malignancy such as rim arterial-phase hyperenhancement or peripheral washout appearance |
Notes: See Table 2 for LI-RADS classifications.
Abbreviations: LI-RADS, Liver Imaging Reporting and Data System; HCC, hepatocellular carcinoma.